Hikma Pharmaceuticals (LON:HIK) Stock Crosses Above Two Hundred Day Moving Average - Here's What Happened

Key Points

• Hikma Pharmaceuticals shares crossed above their 200-day moving average, reaching GBX 1,609 and closing at GBX 1,602, up 1.0% during trading.
• Analysts remain bullish: six analysts rate the stock a Buy, with a consensus price target of GBX 2,085.83; recent target increases included Berenberg’s move to GBX 2,100 and Citi’s to GBX 1,870.
• Insider Tobias Hestler purchased 7,500 shares for approximately £123,600, while insiders collectively own 22.26% of the company.

Hikma Pharmaceuticals PLC (LON:HIK - Get Free Report) shares crossed above its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of GBX 1,511.08 and traded as high as GBX 1,609. Hikma Pharmaceuticals shares last traded at GBX 1,602, with a volume of 522,798 shares.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on HIK shares. Berenberg Bank increased their price objective on shares of Hikma Pharmaceuticals from GBX 1,800 to GBX 2,100 and gave the stock a "buy" rating in a research report on Tuesday, August 11th. Citigroup boosted their target price on shares of Hikma Pharmaceuticals from GBX 1,700 to GBX 1,870 and gave the company a "buy" rating in a report on Wednesday, August 12th. Jefferies Financial Group restated a "buy" rating and issued a GBX 2,025 target price on shares of Hikma Pharmaceuticals in a report on Friday, September 25th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a "buy" rating and set a GBX 1,950 price target on shares of Hikma Pharmaceuticals in a research report on Friday, August 7th. Six analysts have rated the stock with a Buy rating. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of GBX 2,085.83.

Hikma Pharmaceuticals Trading Up 1.0%

The company has a current ratio of 1.98, a quick ratio of 1.27 and a debt-to-equity ratio of 77.57. The firm has a 50-day moving average of GBX 1,609.97 and a 200 day moving average of GBX 1,511.08. The company has a market cap of £3.32 billion, a P/E ratio of 9.10, a price-to-earnings-growth ratio of 2.38 and a beta of 0.66.

Insiders Place Their Bets

In other Hikma Pharmaceuticals news, insider Tobias Hestler bought 7,500 shares of the stock in a transaction on Monday, August 10th. The stock was acquired at an average cost of GBX 1,648 per share, for a total transaction of £123,600. Insiders own 22.26% of the company's stock.

About Hikma Pharmaceuticals

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.